| Name | Title | Contact Details |
|---|
Cambridge Biomedical Inc. is a specialized CRO serving the diverse requirements of the CRO and Biopharmaceutical/Pharmaceutical and Diagnostic markets, utilizing its multi-platform laboratory science capabilities and state of the art systems and procedures. We provide our clients with assay development, assay validation and testing services in support of their clinical trial and pharmaceutical development objectives. Our breadth of experience in laboratory science uniquely positions Cambridge Biomedical to serve as trusted advisor to our clients and provide value-added services beyond the requirements of the project. We are committed to developing each service engagement into a long term relationship.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. We currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! Our employees can be found collaborating across the United States, Europe and Asia. As a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases.
The healthcare industry is at a critical juncture, where every effort is being made to increase the effectiveness of care, while decreasing the financial burden on our system. With the introduction of BioTelemetry, we aim to lead in the advancement of mobile health monitoring by providing unmatched products and services to help healthcare professionals track and diagnose patients in a more efficient, accurate, and cost-effective manner. In April 2013, our predecessor company, CardioNet, Inc. (NASDAQ: BEAT), announced plans to adopt a holding company structure to more effectively facilitate our ongoing growth plans. With this change, our strategy is to achieve sustained long-term growth by solidifying our leadership position in remote cardiac monitoring, building a leading research services business, and identifying markets that would benefit from the application of our wireless platform and proprietary technology. We currently have four subsidiaries: CardioNet & Mednet- cardiac medical device & monitoring services, Braemar- cardiac manufacturing, Cardiocore- cardiac clinical research. Please visit our subsidiary pages for more information.
Blood Center of Iowa is a Des Moines, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Haptica is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.